LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Twist Bioscience Corp

Fechado

SetorSaúde

47.39 -3.64

Visão Geral

Variação de preço das ações

24h

Atual

Mín

46.88

Máximo

50.52

Indicadores-chave

By Trading Economics

Rendimento

-3.4M

-31M

Vendas

4.7M

104M

Margem de lucro

-29.419

Funcionários

979

EBITDA

-3.2M

-24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+9.54% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

309M

2.9B

Abertura anterior

51.03

Fecho anterior

47.39

Sentimento de Notícias

By Acuity

50%

50%

149 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de fev. de 2026, 23:47 UTC

Ações em Alta

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 de fev. de 2026, 22:59 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Grab Holdings to Buy U.S.-Based Stash Financial

11 de fev. de 2026, 23:54 UTC

Ganhos

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 de fev. de 2026, 23:50 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

11 de fev. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 de fev. de 2026, 23:49 UTC

Ganhos

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 de fev. de 2026, 23:45 UTC

Ganhos

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 de fev. de 2026, 23:42 UTC

Ganhos

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 de fev. de 2026, 23:41 UTC

Ganhos

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 de fev. de 2026, 23:40 UTC

Ganhos

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 de fev. de 2026, 23:35 UTC

Conversa de Mercado

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 de fev. de 2026, 23:18 UTC

Conversa de Mercado

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 de fev. de 2026, 23:14 UTC

Conversa de Mercado

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 de fev. de 2026, 22:58 UTC

Ganhos

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 de fev. de 2026, 22:57 UTC

Ganhos

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 de fev. de 2026, 22:54 UTC

Ganhos

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 de fev. de 2026, 22:53 UTC

Ganhos

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 de fev. de 2026, 22:47 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 de fev. de 2026, 22:47 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 de fev. de 2026, 22:23 UTC

Ganhos

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 de fev. de 2026, 22:22 UTC

Ganhos

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 de fev. de 2026, 22:22 UTC

Ganhos

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 de fev. de 2026, 22:19 UTC

Ganhos

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 de fev. de 2026, 22:16 UTC

Ganhos

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

9.54% parte superior

Previsão para 12 meses

Média 52 USD  9.54%

Máximo 58 USD

Mínimo 50 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

149 / 352 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat